Phiri et al, preprint

1 Severe acute malnutrition promotes bacterial binding over pro-inflammatory cytokine

2 secretion by circulating innate immune cells

3

4 AUTHORS

- 5 Tracy N. Phiri¹[†], Kuda Mutasa²[†], Sandra Rukobo²[†], Margaret Govha²[†], Patience
- 6 Mushayanembwa²[†], Simutanyi Mwakamui¹, Tafhima Haider³, Kanekwa Zyambo¹, Cherlynn
- 7 Dumbura², Joice Tome², Thompson Runodamoto², Leah Chidamba², Florence D. Majo²,
- 8 Deophine Ngosa¹, Kanta Chandwe¹, Chanda Kapoma¹, Benjamin Mwapenya², Jonathan P.
- 9 Sturgeon^{2, 3}, Ruairi C. Robertson³, Melanie Smuk³, Robert Ntozini², Kusum Nathoo⁴,
- 10 Beatrice Amadi¹, Paul Kelly^{1, 3}, Mutsa Bwakura-Dangarembizi^{2, 4}, Andrew J. Prendergast^{2, 3},
- and <u>Claire D. Bourke^{2, 3}*</u> on behalf of the HOPE-SAM study team
- 12

13 **AFFILIATIONS**

- ¹⁴ ¹Tropical Gastroenterology and Nutrition group (TROPGAN), University of Zambia School
- 15 of Medicine, Lusaka, Zambia.
- ¹⁶ ²Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe.
- ¹⁷ ³Blizard Institute, Queen Mary University of London, London, UK.
- ⁴Department of Paediatrics and Child Health, University of Zimbabwe College of Health
- 19 Sciences, Harare, Zimbabwe.
- 20 [†] These authors contributed equally to this work
- 21 * Corresponding author: <u>c.bourke@qmul.ac.uk</u>
- 22

23 **KEYWORDS**

- 24 Children; Undernutrition; Zimbabwe; Zambia; Hospital; Innate immunity; Monocytes;
- 25 Neutrophils; Cytokines; Bacteria; Infection NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Phiri et al, preprint

26 ABSTRACT

Children with severe acute malnutrition (SAM) are at high risk of infectious mortality and 27 morbidity during and after hospital discharge. This risk persists despite nutritional and 28 29 prophylactic antibiotic interventions among children with SAM, implicating persistent deficits in their immune defenses. Here we test the hypothesis that innate immune cells from children 30 (0-59 months) hospitalized with SAM in Zambia and Zimbabwe (n=141) have distinct capacity 31 to respond to bacteria relative to adequately-nourished healthy controls from the same 32 communities (n=92). Neutrophils and monocytes from SAM inpatients had a higher capacity 33 34 to bind E. coli but lower monocyte activation and pro-inflammatory mediator secretion in response to E. coli lipopolysaccharide (LPS) or heat-killed Salmonella typhimurium (HKST) 35 than controls. Bacterial binding capacity differentiated children with SAM from controls after 36 37 adjusting for clinical and demographic heterogeneity and normalized with duration of hospital treatment. Wasting severity, HIV status, and age group were associated with LPS and HKST-38 induced cytokine secretion, monocyte activation, and myeloperoxidase secretion, respectively. 39 Bacterial binding capacity and monocyte activation during hospitalization were associated with 40 higher odds of persistent SAM at discharge; a risk factor for subsequent mortality. Thus, SAM 41 shifts anti-bacterial innate immune cell function, favoring bacterial containment over pro-42 inflammatory activation upon challenge, which contributes to persistent health deficits among 43 hospitalized children. 44

45

46 **TEASER**

Children with severe acute malnutrition have distinct anti-bacterial innate immune cell
function compared to healthy children which persists during their hospitalization and
contributes to persistent wasting.

Phiri et al, preprint

51 MAIN TEXT

52

Wasting is a form of undernutrition that affects 6.7% of all children under 5 years old (45.4 53 million) globally, 89% of whom live in low or low-to-middle income countries (LMIC)(1). 54 Severe acute malnutrition (SAM) is the most life-threatening form of wasting, clinically 55 characterized as severe wasting (weight-for-height Z score (WHZ) \leq -3 and/or mid-upper arm 56 circumference (MUAC) <115 mm, for children aged 6–59 months (mo)) with or without 57 bilateral pitting edema(1, 2). Children with clinical complications of SAM requiring hospital 58 admission (i.e. one of the Integrated Management of Childhood Illness clinical danger signs, 59 acute infection, severe edema, or feeding problems(1)) are at particularly high risk of mortality; 60 a meta-analysis of 19 studies among children under 5 years old conducted in 8 African 61 countries found a mean all-cause mortality during hospitalization of 15.7% (95% confidence 62 interval (CI): 10.4, 21.0)(3). Such high inpatient mortality rates and the persistent wasting that 63 64 affects survivors of SAM, compromise ambitious global development goals to reduce global under 5 mortality, reduce and maintain childhood wasting to less than 5% by 2025 (3% by 65 2030), and achieve zero hunger(4, 5). Despite its definition according to anthropometry, it is 66 increasingly recognized that complicated SAM is a combination of conditions rather than a 67 single disorder(3, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6, 6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(6-9) with poor clinical outcomes before and after discharge from hospital(668 9-11) and a pathophysiology that is not fully understood. 69

70

Pathogen carriage is common among children with complicated SAM at hospital admission(8, *10, 12-16*) and empirical antibiotic treatment is therefore recommended even in the absence of infectious symptoms(2). Infections also worsen clinical outcomes among children with SAM: infections independently predict inpatient mortality(*3*), bacteremia is a frequent complication among children who die in hospital(*16*), and the risk of infectious mortality increases incrementally with the severity of wasting(*17*). However, pathogen carriage can be also be high

Phiri et al, preprint

77 among non-wasted children in LMIC(18, 19) and children with SAM appear susceptible to a range of pathogen species and types(8, 10, 12-16), suggesting that poor clinical outcomes 78 among children with SAM reflect a reduced capacity to prevent and contain infection rather 79 80 than infection carriage per se. Consistent with this hypothesis, children with both wasting and stunting have higher circulating levels of pathogen associated molecular patterns (PAMP), 81 including bacterial endotoxin (also termed lipopolysaccharide, LPS) and flagellin(18, 20-23), 82 which are thought to derive from both disseminated infections and from chronic translocation 83 of commensal microbes, PAMP and microbial metabolites across their compromised gut 84 85 barrier. Elevated systemic levels of pro-inflammatory biomarkers correspond with circulating PAMP levels in undernourished children(24), and this inflammatory state is associated with 86 mortality among children with complicated SAM during hospitalization and after discharge(15, 87 25, 26), and positively correlated with metabolic disturbances associated with inpatient 88 mortality(26). In other clinical conditions, such as gram-negative sepsis, systemic circulation 89 of bacterial PAMP drives functional adaptation of circulating immune cells to limit lethal 90 91 systemic inflammation(27, 28) but may also compromise defense against new infectious challenges(29-32). Multiple innate and adaptive immune mediators are dysregulated in 92 undernourished children(24, 33, 34), indicative of an altered immune phenotype. However, few 93 studies have directly assessed the capacity of immune cells to respond to new challenges 94 (immune cell function) among cohorts of undernourished children adequately powered for their 95 inherent clinical, demographic and immune heterogeneity; fewer still have evaluated how 96 clinical characteristics of complicated SAM influence immune function relative to healthy 97 controls from the same community(24, 33, 34). 98

99

In this study we evaluated how innate immune cells from children under 5 years old admitted
 to hospitals in Zambia and Zimbabwe with complicated SAM respond to bacterial PAMP

| 102 | challenge <i>in vitro</i> ; a model for how each child might respond to a newly-acquired infection. |
|---|--|
| 103 | We focused on gram-negative bacterial stimuli derived from species frequently identified in |
| 104 | clinical isolates from children with complicated SAM (Escherichia coli (E. coli) and |
| 105 | Salmonella typhimurium (S. typhimurium))(10, 15, 35) and the two most abundant circulating |
| 106 | innate immune cell types, monocytes and neutrophils. We addressed 3 outstanding questions |
| 107 | in nutritional immunology: 1) how does the capacity to respond to bacterial challenge differ |
| 108 | between innate immune cells from children hospitalized with SAM and adequately-nourished |
| 109 | children? 2) Which clinically-relevant characteristics of children with SAM contribute to |
| 110 | heterogeneity in their anti-bacterial innate immune cell function? 3) Does anti-bacterial |
| 111 | innate immune cell function among children with SAM predict nutritional status at hospital |
| 112 | discharge? |
| 113 | |
| 114 | RESULTS |
| | |
| 115 | Demographic and clinical characteristics of the study cohort |
| 115 116 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples |
| 115 116 117 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples from 141 children under 5 years old who were hospitalized with complicated SAM (defined |
| 115 116 117 118 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples from 141 children under 5 years old who were hospitalized with complicated SAM (defined according to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with no |
| 115 116 117 118 119 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples from 141 children under 5 years old who were hospitalized with complicated SAM (defined according to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with no symptoms of infection (healthy controls; Table 1). All children were participants in a |
| 115 116 117 118 119 120 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples from 141 children under 5 years old who were hospitalized with complicated SAM (defined according to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with no symptoms of infection (healthy controls; Table 1). All children were participants in a longitudinal observational cohort study of the health outcomes and pathogenesis of SAM |
| 115 116 117 118 119 120 121 | Demographic and clinical characteristics of the study cohortWe undertook anti-bacterial innate immune cell function assessment using blood samplesfrom 141 children under 5 years old who were hospitalized with complicated SAM (definedaccording to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with nosymptoms of infection (healthy controls; Table 1). All children were participants in alongitudinal observational cohort study of the health outcomes and pathogenesis of SAM(HOPE-SAM(36)) which recruited from 3 peri-urban tertiary hospital sites in Zambia |
| 115 116 117 118 119 120 121 122 | Demographic and clinical characteristics of the study cohortWe undertook anti-bacterial innate immune cell function assessment using blood samplesfrom 141 children under 5 years old who were hospitalized with complicated SAM (definedaccording to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with nosymptoms of infection (healthy controls; Table 1). All children were participants in alongitudinal observational cohort study of the health outcomes and pathogenesis of SAM(HOPE-SAM(36)) which recruited from 3 peri-urban tertiary hospital sites in Zambia(University Teaching Hospital, Lusaka) and Zimbabwe (Harare Central and Parirenyatwa) |
| 115 116 117 118 119 120 121 122 123 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples from 141 children under 5 years old who were hospitalized with complicated SAM (defined according to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with no symptoms of infection (healthy controls; Table 1). All children were participants in a longitudinal observational cohort study of the health outcomes and pathogenesis of SAM (HOPE-SAM(36)) which recruited from 3 peri-urban tertiary hospital sites in Zambia (University Teaching Hospital, Lusaka) and Zimbabwe (Harare Central and Parirenyatwa |
| 115 116 117 118 119 120 121 122 123 124 | Demographic and clinical characteristics of the study cohortWe undertook anti-bacterial innate immune cell function assessment using blood samplesfrom 141 children under 5 years old who were hospitalized with complicated SAM (definedaccording to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with nosymptoms of infection (healthy controls; Table 1). All children were participants in alongitudinal observational cohort study of the health outcomes and pathogenesis of SAM(HOPE-SAM(36)) which recruited from 3 peri-urban tertiary hospital sites in Zambia(University Teaching Hospital, Lusaka) and Zimbabwe (Harare Central and ParirenyatwaHospitals, Harare); inclusion of HOPE-SAM participants in this study is shown in Figure S1. |
| 115 116 117 118 119 120 121 122 123 124 125 | Demographic and clinical characteristics of the study cohort We undertook anti-bacterial innate immune cell function assessment using blood samples from 141 children under 5 years old who were hospitalized with complicated SAM (defined according to WHO criteria(1)) and 92 adequately-nourished (WHZ>-1) children with no symptoms of infection (healthy controls; Table 1). All children were participants in a longitudinal observational cohort study of the health outcomes and pathogenesis of SAM (HOPE-SAM(36)) which recruited from 3 peri-urban tertiary hospital sites in Zambia (University Teaching Hospital, Lusaka) and Zimbabwe (Harare Central and Parirenyatwa Hospitals, Harare); inclusion of HOPE-SAM participants in this study is shown in Figure S1. Chough all participants in the SAM group were critically unwell, they tended to be healthier |

Phiri et al, preprint

127

| 128 | Innate immune cell function was characterized in the SAM group (Table 1) using the first |
|---|--|
| 129 | available venous blood sample ($\geq 2mL$) collected during their inpatient period (median time |
| 130 | from admission to immune function assessment (time to immunoassay): 6.0 days, |
| 131 | interquartile range (IQR): 4, 11); 38.2% of the SAM group had their first immune function |
| 132 | assessment on the day of discharge from hospital. Clinical symptoms were recorded daily |
| 133 | during hospitalization with 80.8% of children in the SAM group having ongoing clinical |
| 134 | complications and 60.0% having symptoms indicative of acute infection at the time of |
| 135 | immune function assessment (Table S2). All children who had immune function assessment |
| 136 | during hospitalization survived to hospital discharge, spending a median of 11.0 (IQR: 7.0, |
| 137 | 16.0) days in hospital. Healthy controls had a venous blood sample collected for immune |
| 138 | function assessment at enrolment. |
| 139 | |
| 140 | 22 shildren in the SAM group (22.40() and 22 shildren in the healthy control group (24.80()) |
| | 55 children in the SAM group (25.4%) and 52 children in the heating control group (54.8%) |
| 141 | were living with HIV. 42.4% of HIV-positive children in the SAM group were on |
| 141 142 | were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the |
| 141 142 143 | were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the healthy control group were on ART. |
| 141 142 143 144 | were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the healthy control group were on ART. |
| 141 142 143 144 145 | SS children in the SAM group (23.4%) and 32 children in the healthy control group (34.8%) were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the healthy control group were on ART. Consistent with previous studies(24, 33, 34), children with complicated SAM had higher |
| 141 142 143 144 145 146 | SS children in the SAM group (23.4%) and S2 children in the heating control group (34.8%) were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the healthy control group were on ART. Consistent with previous studies(24, 33, 34), children with complicated SAM had higher concentrations of systemic and intestinal inflammatory biomarkers relative to healthy |
| 141 142 143 144 145 146 147 | S5 children in the SAM group (25.4%) and 52 children in the healthy control group (54.8%) were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the healthy control group were on ART. Consistent with previous studies(24, 33, 34), children with complicated SAM had higher concentrations of systemic and intestinal inflammatory biomarkers relative to healthy controls (Table 1); these included elevated monocyte/macrophage-derived surface marker |
| 141 142 143 144 145 146 147 148 | S5 children in the SAM group (23.4%) and 32 children in the healthy control group (34.8%) were living with HIV. 42.4% of HIV-positive children in the SAM group were on antiretroviral therapy (ART) at hospital admission and 100% of HIV-positive children in the healthy control group were on ART. Consistent with previous studies(24, 33, 34), children with complicated SAM had higher concentrations of systemic and intestinal inflammatory biomarkers relative to healthy controls (Table 1); these included elevated monocyte/macrophage-derived surface marker levels (sCD14, sCD163), acute phase proteins (CRP) and LPS-binding protein (LBP) in |

150

151 SAM enhances the capacity of innate immune cells to bind bacteria

Phiri et al, preprint

| 152 | To quantify the capacity of blood immune cells to bind to bacteria, we incubated whole blood |
|-----|--|
| 153 | samples from each child either without stimulus (negative control) or with E. coli-coated |
| 154 | bioparticles labelled with a fluorescent dye (AlexaFluor 488, AF488) at 37°C for 1h and |
| 155 | analyzed cell-type specific binding to <i>E. coli</i> via flow cytometry (Figure S2). This assay |
| 156 | identifies cells that have either bound or internalized the bioparticles and therefore reflects |
| 157 | both bacterial binding and phagocytic capacity. The SAM and healthy control groups had |
| 158 | similar total leukocyte counts, and percentages of lymphocytes (positive for any lymphocyte |
| 159 | lineage marker (Lin): CD3, CD19, CD20 and/or CD56) and neutrophils (Lin- |
| 160 | CD66b+CD16+) in unstimulated cultures (Table S3; Figure S3). Percentages of monocytes |
| 161 | (Lin-CD66b-HLA-DR+) were slightly lower in unstimulated cultures from the SAM group |
| 162 | (median: 2.3%; IQR: 1.3, 4.0) versus healthy control group (3.7%, IQR: 2.7, 5.3; p=0.004) |
| 163 | with lower percentages of classical monocytes (CD14 ^{hi} CD16-; median: 30.6% (IQR: 16.2, |
| 164 | 41.0) versus 35.5% (IQR: 26.4, 46.4); p=0.025), higher percentages of intermediate |
| 165 | monocytes (CD14 ^{hi} CD16+; median: 12.0% (IQR: 7.8, 16.0) versus 8.3% (IQR: 5.9, 11.9); |
| 166 | p<0.001) and similar percentages of non-classical monocytes (CD14 ^{lo} CD16+; median: 29.8% |
| 167 | (IQR: 18.1, 40.1) versus 32.7% (IQR: 22.7, 41.2); p=0.410). The classical, intermediate and |
| 168 | non-classical monocyte sub-sets reflect a maturation continuum(37), expanded intermediate |
| 169 | monocytes therefore reflect increased circulating monocyte activation and maturation in |
| 170 | SAM versus healthy controls. Unstimulated cultures for both groups had negligible <i>E. coli</i> + |
| 171 | events and AF488 meanFIs (Figure S2B; Table S4). |
| | |

172

173 After incubation with *E. coli*-bioparticles, there were higher median percentages of *E. coli*+

174 leukocytes in the SAM versus healthy control group (**Figure 1A**); evaluation of standardized

numbers of *E. coli*+ leukocytes from each participant (500 events/participant) via t-

176 distributed stochastic neighbor embedding (tSNE; **Figure 1B**) and clustering of *E.coli*+ cell

Phiri et al, preprint

| 177 | types according to their cell surface marker expression via flow cytometry self-organizing |
|-----|--|
| 178 | maps (FlowSOM; Figure S4) identified compositional differences in the immune cell types |
| 179 | that bound bacteria in samples from the SAM versus healthy control group. There was no |
| 180 | difference in total leukocyte count (Figure 1C), however <i>E. coli</i> + leukocyte count (Figure |
| 181 | 1D) and percentage of <i>E. coli</i> + leukocytes (Figure 1E) were higher in the SAM versus |
| 182 | healthy control group; analyses are summarized in Table S4. E. coli meanFI of total |
| 183 | leukocytes were lower in the SAM group relative to healthy controls (Figure 1F), indicative |
| 184 | of lower mean amounts of bioparticles bound per-cell. Neutrophils made up a higher |
| 185 | percentage, lymphocytes a lower percentage and monocytes a similar percentage of E. coli+ |
| 186 | leukocytes in the SAM versus healthy control group (Figure 1G). Within the monocyte |
| 187 | population, classical monocytes made up a lower percentage of <i>E. coli</i> + monocytes and the |
| 188 | more differentiated intermediate monocyte phenotype made up a higher percentage of E. |
| 189 | coli+ monocytes in the SAM versus healthy control group (Figure 1H). |
| 190 | |

To evaluate the cell-type specific capacity for *E. coli* binding, independent of compositional 191 differences in the cell types present in the initial unstimulated blood sample, we compared E. 192 *coli*+ percentages of lymphocytes, neutrophils, monocytes and monocyte sub-sets between 193 groups. A higher percentage of all 3 cell types (Figure 1I) and all monocytes sub-sets 194 (Figure 1J) bound to *E. coli* in the SAM group compared to the healthy control group, 195 indicative of a generalized enhancement of cell-type specific bacterial binding capacity in the 196 context of SAM which was more pronounced in neutrophils (fractional regression coefficient: 197 1.50, 95% CI: 1.19, 1.81; p<0.001) and monocytes (coefficient: 1.47, 95% CI: 1.15, 1.79; 198 p<0.001) than in lymphocytes (coefficient: 0.90, 95% CI: 0.65, 1.15; p<0.001). Neutrophils 199 from the SAM group had higher AF488 meanFI (Figure 1K), lymphocytes had lower 200 meanFI (Figure 1L), and total monocytes (Figure 1M) and all monocyte sub-sets had higher 201

Phiri et al, preprint

| 208 | to bacteria |
|-----|--|
| 207 | SAM reduces monocyte activation and pro-inflammatory cytokine secretion in response |
| 206 | |
| 205 | bacterial binding by neutrophils and monocytes. |
| 204 | S3) reflected lower bacterial binding per-lymphocyte in the SAM group despite their higher |
| 203 | total leukocytes in the SAM group (Figure 1F; >50% of leukocytes in both groups; Figure |
| 202 | meanFI (Figure 1N) than those from the healthy control group. Thus, the lower meanFI for |

Upregulation of major histocompatibility complexes (e.g. HLA-DR) and co-receptors (e.g. 210 CD86 and CD40) required for activation of T cells, and secretion of soluble mediators to mobilize anti-bacterial functions in other cells and tissues, recruit immune cells, and promote 211 bactericidal reactive oxygen species (ROS) production are key features of the innate immune 212 213 response to bacterial infection. We quantified these characteristics in immune cells and supernatants from parallel 24h whole blood cultures conducted without stimulus (negative 214 controls) and with bacterial PAMP (E. coli LPS and heat-killed S. typhimurium (HKST)). 215 216 Unstimulated whole blood cultures from children with SAM had higher percentages of neutrophils, and a more mature monocyte phenotype than those from healthy controls 217 (Figure S5A-B; Table S3). Unstimulated monocytes from children with SAM expressed 218 lower levels of HLA-DR (medianFI) than healthy controls but similar levels of CD86 and 219 CD40 (Figure S5C-E; Table S5). Basal concentrations of pro-inflammatory cytokines (IL-6, 220 221 IL-8 and TNF α) in unstimulated whole blood culture supernatants were similar in the two groups (Figure S5F; Table S5). Basal concentrations of myeloperoxidase (MPO), an enzyme 222 which catalyzes production of ROS, were higher in culture supernatants from the SAM 223 224 versus healthy control group (Figure S5F; Table S5).

225

| 226 | To account for unstimulated differences between the two groups and focus on the capacity of |
|---|--|
| 227 | immune cells to respond to a new bacterial challenge in vitro, we calculated PAMP-induced |
| 228 | cell surface marker expression and mediator secretion for each child by subtracting HLA-DR, |
| 229 | CD86 and CD40 medianFIs and mediator concentrations present in their corresponding |
| 230 | unstimulated cultures (Δ); Δ median FIs/concentrations were censored at zero (i.e. no increase |
| 231 | in response to PAMP). Monocytes from children with SAM had lower LPS-induced |
| 232 | Δ medianFI for HLA-DR, CD86 and CD40 than those from healthy controls (Figure 2A-D ; |
| 233 | Table S5). The same pattern was observed for HKST-induced monocyte surface marker |
| 234 | Δ medianFI but with stronger evidence for a difference in HKST-induced CD40 than for |
| 235 | HKST-induced HLA-DR and CD86 (Figure 2B-D; Table S5). LPS- and HKST-induced IL- |
| 236 | 6, IL-8, TNF α and MPO were all lower in supernatants from cultures conducted with blood |
| 237 | samples from SAM versus healthy controls (Figure 2E-F; Table S5). |
| 238 | |
| 250 | |
| 239 | Monocytes and neutrophils from children with SAM prioritize bacterial containment |
| 239 240 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation |
| 230239240241 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell |
| 239 240 241 242 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of |
| 239 240 241 242 243 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of neutrophil and monocyte function that explained the immune heterogeneity in our cohort via |
| 239 240 241 242 243 244 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of neutrophil and monocyte function that explained the immune heterogeneity in our cohort via principal components analysis (PCA) of all read-outs. 126/141 children (89.4%) in the SAM |
| 239 240 241 242 243 244 245 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of neutrophil and monocyte function that explained the immune heterogeneity in our cohort via principal components analysis (PCA) of all read-outs. 126/141 children (89.4%) in the SAM |
| 239 240 241 242 243 244 245 246 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of neutrophil and monocyte function that explained the immune heterogeneity in our cohort via principal components analysis (PCA) of all read-outs. 126/141 children (89.4%) in the SAM group and 73/92 children (79.3%) in the healthy control group had complete data for all variables which were included in a single PCA. We identified 5 groups of anti-bacterial |
| 239 240 241 242 243 244 245 246 247 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of neutrophil and monocyte function that explained the immune heterogeneity in our cohort via principal components analysis (PCA) of all read-outs. 126/141 children (89.4%) in the SAM group and 73/92 children (79.3%) in the healthy control group had complete data for all variables which were included in a single PCA. We identified 5 groups of anti-bacterial |
| 239 240 241 242 243 244 245 246 247 248 | Monocytes and neutrophils from children with SAM prioritize bacterial containment over systemic immune activation Having identified differences in individual read-outs of anti-bacterial innate immune cell function between the SAM and healthy control groups, we sought to characterize patterns of neutrophil and monocyte function that explained the immune heterogeneity in our cohort via principal components analysis (PCA) of all read-outs. 126/141 children (89.4%) in the SAM group and 73/92 children (79.3%) in the healthy control group had complete data for all variables which were included in a single PCA. We identified 5 groups of anti-bacterial monocyte and neutrophil functions (principal components, PC; Figure 3A): PC1 scores for each participant corresponded to their neutrophil and monocyte bacterial binding capacity; |
| 239 240 241 242 243 244 245 246 247 248 249 | Monocytes and neutrophils from children with SAM prioritize bacterial containmentover systemic immune activationHaving identified differences in individual read-outs of anti-bacterial innate immune cellfunction between the SAM and healthy control groups, we sought to characterize patterns ofneutrophil and monocyte function that explained the immune heterogeneity in our cohort viaprincipal components analysis (PCA) of all read-outs. 126/141 children (89.4%) in the SAMgroup and 73/92 children (79.3%) in the healthy control group had complete data for allwariables which were included in a single PCA. We identified 5 groups of anti-bacterialmonocyte and neutrophil functions (principal components, PC; Figure 3A): PC1 scores foreach participant corresponded to their neutrophil and monocyte bacterial binding capacity;PC2 scores to theirs LPS- and HKST-induced pro-inflammatory cytokine (TNFα, IL-6 and |

Phiri et al, preprint

| 251 | expression; PC4 scores to their LPS- and HKST-induced MPO; and, PC5 scores to a |
|-----|---|
| 252 | combination of their neutrophil bacterial binding and PAMP-induced MPO release (Figure |
| 253 | 3A). PC1-5 collectively captured 72.1% of the variance in our immune function data. |
| 254 | |
| 255 | We then tested our hypothesis that anti-bacterial innate immune cell function differs between |
| 256 | children admitted to hospital with SAM relative to healthy controls from the same |
| 257 | community using linear regression of participant scores for each PC, adjusted for |
| 258 | characteristics that might affect both their nutritional status and their immune function (i.e. |
| 259 | age group, sex, HIV status, hospital site, and assessment of immune function on the same day |
| 260 | as hospital discharge; Figure 3B-F; Table S6). These analyses provide evidence for a total |
| 261 | effect of SAM status on innate immune cell bacterial binding capacity (PC1 scores; adjusted |
| 262 | coefficient: 3.69, 95%CI: 2.97, 4.40, p<0.001) and neutrophil anti-bacterial response (PC5 |
| 263 | scores; adjusted coefficient: 0.33, 95%CI: 0.03, 0.63, p=0.031), consistent with a shift in |
| 264 | innate immune cell function favoring containment of bacteria by binding/phagocytosis. |
| 265 | Despite having higher circulating and intestinal pro-inflammatory biomarker levels relative to |
| 266 | healthy controls (Table 1) and evidence that critically unwell children hospitalized in LMIC |
| 267 | may have enhanced LPS-induced pro-inflammatory cytokine secretion(38), there was limited |
| 268 | evidence that PC2 scores (adjusted coefficient: -0.48, 95%CI: -1.13, 0.16, p=0.143), PC3 |
| 269 | scores (adjusted coefficient: -0.23, 95%CI: -0.73, 0.27, p=0.358) or PC4 scores (adjusted |
| 270 | coefficient: 0.01, 95%CI: -0.39, 0.38, p=0.031) differed by nutritional status after adjusting |
| 271 | for confounders (Figure 3C-E). |
| | |

272

Since HIV status can influence many aspects of SAM and has a profound impact on the
immune system, we undertook sensitivity analysis including only the HIV-negative children
(Figure 4A-E; Table S7; SAM n=101/126 (80.2%), healthy controls n=46/73 (63.0%)); this

| 276 | strengthened the association between SAM status and PC1 (adjusted coefficient: 4.04, |
|---|--|
| 277 | 95%CI: 3.17, 4.91, p<0.001) and PC5 (adjusted coefficient: 0.41, 95%CI: 0.07, 0.76, |
| 278 | p=0.017). Furthermore, because some of our SAM group had immune function assessments |
| 279 | late in the course of their inpatient rehabilitation, we undertook sensitivity analyses only |
| 280 | including children who had their immune function assessed prior to the day of discharge |
| 281 | (Figure 4F-J; Table S8; SAM n=75/126 (59.5%), healthy controls n=73/73 (100%)); this |
| 282 | slightly weakened the effect size but did not affect the direction or significance of the |
| 283 | association between SAM and PC1 scores (adjusted coefficient: 3.80, 95%CI: 3.09, 4.52, |
| 284 | p<0.001) and PC5 scores (adjusted coefficient: 0.36, 95%CI: 0.05, 0.66, p=0.021). There |
| 285 | remained limited evidence to support an association between SAM status and PC2-4 scores |
| 286 | after adjusting for confounders in either sensitivity analysis (Figure 4B-D and G-I). |
| 287 | |
| 288 | Anti-bacterial innate immune cell function is partially shaped by age group, HIV status |
| | |
| 289 | and wasting severity at hospital admission |
| 289 290 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for |
| 289 290 291 | and wasting severity at hospital admissionChildren with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(3, 6-9), which could plausibly impact their immune function |
| 289 290 291 292 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(3, 6-9), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso |
| 289 290 291 292 293 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(3, 6-9), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso linear regression to estimate the effect of variables associated with mortality in the HOPE- |
| 289 290 291 292 293 294 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(3, 6-9), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso linear regression to estimate the effect of variables associated with mortality in the HOPE- SAM cohort (i.e. HIV status, nutritional edema, age group, MUAC at baseline, and |
| 289 290 291 292 293 294 295 | and wasting severity at hospital admissionChildren with complicated SAM experience a range of comorbidities and risk factors foradverse clinical outcomes(3, 6-9), which could plausibly impact their immune functionrelative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lassolinear regression to estimate the effect of variables associated with mortality in the HOPE-SAM cohort (i.e. HIV status, nutritional edema, age group, MUAC at baseline, andsymptoms of infection at the time of immune function assessment(6, 9)) on PC1-5 scores of |
| 289 290 291 292 293 294 295 296 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(<i>3</i> , <i>6-9</i>), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso linear regression to estimate the effect of variables associated with mortality in the HOPE- SAM cohort (i.e. HIV status, nutritional edema, age group, MUAC at baseline, and symptoms of infection at the time of immune function assessment(<i>6</i> , <i>9</i>)) on PC1-5 scores of the SAM group. Other potential sources of immune heterogeneity in the SAM group were |
| 289 290 291 292 293 294 295 296 297 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(<i>3</i> , <i>6-9</i>), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso linear regression to estimate the effect of variables associated with mortality in the HOPE- SAM cohort (i.e. HIV status, nutritional edema, age group, MUAC at baseline, and symptoms of infection at the time of immune function assessment(<i>6</i> , <i>9</i>)) on PC1-5 scores of the SAM group. Other potential sources of immune heterogeneity in the SAM group were offered to the model as control variables (i.e. sex, hospital site, time to immunoassay (days), |
| 289 290 291 292 293 294 295 296 297 298 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(<i>3</i> , <i>6-9</i>), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso linear regression to estimate the effect of variables associated with mortality in the HOPE- SAM cohort (i.e. HIV status, nutritional edema, age group, MUAC at baseline, and symptoms of infection at the time of immune function assessment(<i>6</i> , <i>9</i>)) on PC1-5 scores of the SAM group. Other potential sources of immune heterogeneity in the SAM group were offered to the model as control variables (i.e. sex, hospital site, time to immunoassay (days), immune assessment on the day of discharge, height-for-age Z score (HAZ), WHZ, cerebral |
| 289 290 291 292 293 294 295 296 297 298 299 | and wasting severity at hospital admission Children with complicated SAM experience a range of comorbidities and risk factors for adverse clinical outcomes(<i>3</i> , <i>6-9</i>), which could plausibly impact their immune function relative to healthy controls. To explore this hypothesis, we used cross-fit partialling-out lasso linear regression to estimate the effect of variables associated with mortality in the HOPE- SAM cohort (i.e. HIV status, nutritional edema, age group, MUAC at baseline, and symptoms of infection at the time of immune function assessment(<i>6</i> , <i>9</i>)) on PC1-5 scores of the SAM group. Other potential sources of immune heterogeneity in the SAM group were offered to the model as control variables (i.e. sex, hospital site, time to immunoassay (days), immune assessment on the day of discharge, height-for-age Z score (HAZ), WHZ, cerebral palsy status, and birthweight (g)). 109/126 (86.5%) of children had complete data on all |

| 3 | 0 | 1 |
|---|---|---|
| | | |

| 302 | We did not find evidence to support an independent effect of clinically-important variables |
|--|---|
| 303 | on PC1 or PC5 scores (Table 2). However, we found evidence to support a positive |
| 304 | association between PC2 scores and baseline MUAC (adjusted coefficient: 0.04, 95%CI: |
| 305 | 0.01, 0.07, p=0.010; Figure 5A), a negative association between PC3 scores and HIV |
| 306 | infection (adjusted coefficient: -0.66, 95%CI: -1.28, -0.04, p=0.037; Figure 5B), and a |
| 307 | positive association between PC4 scores and age group; children in the 12-23mo (adjusted |
| 308 | coefficient: 0.39, 95%CI: -0.42, 1.20, p=0.348) and 24-59mo (adjusted coefficient: 1.16, |
| 309 | 95%CI: 0.24, 2.08, p=0.013) age groups had higher PC4 scores than the youngest age group |
| 310 | (0-11mo; Figure 5C). The best evidence that clinically important exposure variables |
| 311 | influenced anti-bacterial innate immune cell function came from the PC4 model (Wald chi ² : |
| 312 | 13.74, p=0.033) with weaker evidence from models for the other PCs (Table 2). |
| 212 | |
| 313 | |
| 313 314 | Anti-bacterial innate immune cell function normalizes with duration of inpatient |
| 313314315 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation |
| 313314315316 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical |
| 313 314 315 316 317 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so |
| 313 314 315 316 317 318 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(1). Given that |
| 313 314 315 316 317 318 319 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(1). Given that all children in the SAM group survived to discharge, we hypothesized that those who had a |
| 313 314 315 316 317 318 319 320 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(<i>1</i>). Given that all children in the SAM group survived to discharge, we hypothesized that those who had a longer period of inpatient rehabilitation prior to their immune function assessment (time to |
| 313 314 315 316 317 318 319 320 321 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(1). Given that all children in the SAM group survived to discharge, we hypothesized that those who had a longer period of inpatient rehabilitation prior to their immune function assessment (time to immunoassay) would have innate immune cell function more similar to healthy controls than |
| 313 314 315 316 317 318 319 320 321 322 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(1). Given that all children in the SAM group survived to discharge, we hypothesized that those who had a longer period of inpatient rehabilitation prior to their immune function assessment (time to immunoassay) would have innate immune cell function more similar to healthy controls than those assessed at hospital admission. We found cross-sectional evidence for a negative |
| 313 314 315 316 317 318 319 320 321 322 323 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(1). Given that all children in the SAM group survived to discharge, we hypothesized that those who had a longer period of inpatient rehabilitation prior to their immune function assessment (time to immunoassay) would have innate immune cell function more similar to healthy controls than those assessed at hospital admission. We found cross-sectional evidence for a negative association between PC1 (Figure 6A ; adjusted coefficient: -0.10, 95%CI: -0.15, -0.05, |
| 313 314 315 316 317 318 319 320 321 322 323 324 | Anti-bacterial innate immune cell function normalizes with duration of inpatient rehabilitation Inpatient rehabilitation of children with complicated SAM aims to resolve clinical complications, including acute infections, and begin nutritional stabilization and recovery so that children can be discharged to outpatient community management of SAM(<i>I</i>). Given that all children in the SAM group survived to discharge, we hypothesized that those who had a longer period of inpatient rehabilitation prior to their immune function assessment (time to immunoassay) would have innate immune cell function more similar to healthy controls than those assessed at hospital admission. We found cross-sectional evidence for a negative association between PC1 (Figure 6A ; adjusted coefficient: -0.10, 95%CI: -0.15, -0.05, p<0.001) and PC5 (Figure 6E ; adjusted coefficient: -0.03, 95%CI: -0.05, 0.01, p=0.040) and |

Phiri et al, preprint

| 326 | immunoassay, and immune function assessment on the day of discharge (Table S9). We did |
|-----|--|
| 327 | not find substantial evidence that anti-bacterial pro-inflammatory cytokine secretion (PC2; |
| 328 | adjusted coefficient: -0.01, 95%CI: -0.06, 0.04, p=0.784), upregulation of monocyte |
| 329 | activation markers in response to bacterial PAMP (PC3; adjusted coefficient: 0.00, 95%CI: - |
| 330 | 0.04, 0.04, p=0.981) or PAMP-induced MPO production (PC4; adjusted coefficient: 0.02, |
| 331 | 95%CI: -0.02, 0.06, p=0.295) changed with time to immunoassay (Figure 6B-D ; Table S9). |
| 332 | |
| 333 | Anti-bacterial immune function during hospitalization is associated with persistent |
| 334 | SAM at discharge |
| 335 | In the HOPE-SAM cohort, children with persistent SAM at discharge were at greater risk of |
| 336 | subsequent mortality and had persistently lower WHZ and MUAC throughout 1 year of post- |
| 337 | discharge follow-up than children who were discharged with moderate acute malnutrition |
| 338 | (MAM) or adequate nutrition(9). In light of our observations that children with SAM had a |
| 339 | distinct bacterial binding capacity to healthy controls, and cross-sectional evidence that these |
| 340 | differences may normalize during inpatient rehabilitation, we hypothesized that immune |
| 341 | function would be associated with persistent SAM at hospital discharge. We tested this |
| 342 | hypothesis in children with SAM who had immune function assessment prior to the day of |
| 343 | discharge and who were not discharged against medical advice (n=66); 26/66 (39.4%) had |
| 344 | persistent SAM and 40/66 (60.6%) had MAM (-2 <whz<-1; adequate="" n="13)" nutritional<="" or="" td=""></whz<-1;> |
| 345 | status (WHZ>-1; n=27) at discharge (Table S10). |
| 346 | |
| 347 | Unadjusted logistic regression provided limited evidence for anti-bacterial innate immune |
| 348 | function (PC1-5) affecting odds of persistent SAM at discharge (Figure S6; Table S11). |
| 349 | However, after adjusting for confounders (sex, hospital site, HIV status, baseline age group |
| 350 | and baseline MUAC), higher scores for both PC1 (bacterial binding capacity) and PC3 |

Phiri et al, preprint

(monocyte activation) were associated with 1.40 (95% CI: 1.02, 1.92; p=0.037) and 1.56
(95% CI: 1.04, 2.34; p=0.033) higher odds of persistent SAM at discharge, respectively
(Figure 6F; Table S11).

354

355 **DISCUSSION**

Complicated SAM has typically been considered an immunosuppressed state, with functional 356 responses to bacteria thought to reflect the immunoparalysis phenotype described in sepsis and 357 multiple organ dysfunction syndrome(31, 39, 40). Previous pilot studies have found conflicting 358 359 evidence for the capacity of innate immune cells to bind/phagocytose, upregulate activation markers, secrete immune mediators, initiate oxidative burst capacity, and kill bacteria in 360 undernourished children(33, 34). By characterizing multiple domains of innate immune cell 361 362 function simultaneously in an adequately-powered cohort, our data demonstrate that children who survive to hospital discharge achieve a compromise rather than a global deficiency in anti-363 bacterial innate immune cell function. We show that innate immune cells from children with 364 SAM share some of the hallmark features of immunoparalysis, namely lower expression of 365 HLA-DR and co-stimulatory molecules (CD86 and CD40) by monocytes, and lower pro-366 inflammatory cytokine production upon in vitro PAMP challenge (PCs 2-4). This accords with 367 a previous study among 37 children admitted to the University Teaching Hospital, Lusaka with 368 complicated SAM which found that blood dendritic cells (median: 0.51% IQR: 0.34-0.72 of 369 370 peripheral blood mononuclear cells) had impaired IL-12 responses to LPS at hospital admission and a small percentage of children (17%; n=6) failed to upregulate HLA-DR upon LPS-371 stimulation(41). However, in parallel with lower monocyte activation/maturation and pro-372 373 inflammatory mediator secretion, we show that monocyte and neutrophil bacterial binding capacity (PC1 and 5) was markedly higher in the SAM group compared to the healthy control 374 group. Given the association between elevated systemic pro-inflammatory mediators and 375

Phiri et al, preprint

376 mortality from complicated SAM(15, 25, 26), it is plausible that favoring bacterial containment via enhanced binding/phagocytosis over cytokine secretion by innate immune cells would 377 provide a survival advantage during acute hospital admission. A similar adaptive balance has 378 379 been observed for monocytes derived from adults hospitalized with gram-negative sepsis (n=3), which had lower expression of monocyte activation, pro-inflammatory cytokine and 380 chemokine genes coinciding with enhanced phagocytosis and growth inhibition of live E. coli 381 in vitro before versus after recovery(27). This monocyte 're-programming' by sepsis favored 382 angiogenesis and wound healing functions of septic monocytes in vitro which normalized in 383 384 cells collected after recovery(27).

385

In this study we used a whole blood-based in vitro assay of bacterial binding capacity, including 386 plasma components alongside all circulating cell types; the enhanced bacterial binding capacity 387 that we observe in SAM could therefore reflect cell-intrinsic differences in activation, 388 trafficking and expression of phagocytic receptors and/or increased levels of circulating 389 390 bacterial binding proteins and opsonins that accelerate bacterial uptake. The SAM group had higher percentages of intermediate monocytes, which mature from classical monocytes and 391 have higher expression of the Fcy III receptor (CD16), which enhances phagocytosis and 392 degranulation in response to IgG-opsonized bacteria(42); indirect evidence that monocytes 393 from SAM have a more activated/mature phagocytic phenotype than those from healthy 394 controls. Furthermore, concentrations of both LBP and sCD14, which are not phagocytic 395 receptors but can bind gram-negative bacteria, mediate phagocytosis in some settings, and 396 confer responsiveness to bacteria by binding to the membranes of non-monocytic (CD14-) cells 397 398 in complex with LPS(43-45), were higher in plasma from children with SAM versus healthy controls. Recent evidence from experimental animal models supports our data that pathogen 399 binding by innate immune cells is enhanced in the context of undernutrition; cutaneous 400

Phiri et al, preprint

401 monocytes from mice fed polynutrient deficient diets more readily internalized *Leishmania* 402 *donovani* parasites and more *L. donovani*+ monocytes trafficked to the spleen relative to 403 nutrient-sufficient animals(46). The mechanism/s by which bacterial binding capacity of innate 404 immune cells is elevated in children with SAM and what impact this has on their subsequent 405 trafficking to other tissues remains to be determined.

406

Moving beyond the view of SAM solely as an immunosuppressed/anergic state could support 407 stratification of patients according to specific immunological risk factors; for example, a recent 408 409 phase II double-blind trial of immune-based interventions among adults hospitalized with sepsis highlighted that clinical stratification based on hyper-inflammatory versus 410 immunoparalysis phenotypes showed promise for identifying patients at highest mortality risk 411 412 and guiding personalized immunotherapy (i.e. immune 'boosting' with recombinant IFNy for patients with immunoparalysis or immune 'dampening' with Anakinra (a synthetic form of IL-413 1α receptor) for patients with macrophage activation-like syndrome)(47). Of 15 patients 414 415 randomized to immunotherapy, 42.9% survived to 7 days with a decrease in sequential organ failure assessment score, relative to 10.0% of the 21 patients in the placebo arm(47). Notably, 416 only 1 (0.01%) of our cohort of children with complicated SAM was septic at the time of blood 417 sampling. Thus, whilst sepsis provides a pertinent analogue of the systemic endotoxin exposure 418 observed in SAM and a 'sepsis-like' biomarker profile has been described among children 419 420 recovering from SAM who die after hospital discharge(25, 26), SAM presents a distinct clinical and immunological condition. 421

422

423 It is unclear whether previously described differences in immune phenotype in children

424 admitted with complicated SAM reflect nutritional status and/or specific patient

425 characteristics/comorbidities. In the HOPE-SAM cohort, mortality over 1 year of post-

| 426 | discharge follow-up was associated with HIV infection (Adj. Hazard ratio (HR): 3.83; 95% |
|-----|--|
| 427 | CI: 2.15, 6.82), persistent SAM at discharge (Adj. HR: 2.28; 95% CI: 1.22, 4.25), cerebral |
| 428 | palsy (Adj. HR: 5.60; 95% CI: 2.72, 11.50) and non-edematous SAM at admission (Adj. HR: |
| 429 | 2.23; 95% CI: 1.24, 4.01)(9). Young age, SAM at discharge, non-edematous SAM at |
| 430 | admission and cerebral palsy were also associated with hospital readmission or poor |
| 431 | nutritional recovery after discharge(6). Symptoms of acute infection have previously been |
| 432 | implicated in inpatient mortality among children hospitalized with SAM(3). We did not find |
| 433 | evidence that these risk factors for poor clinical outcomes explained variation in scores for |
| 434 | PC1 or PC5, the domains of immune function that best differentiated SAM cases from |
| 435 | healthy controls. Thus, enhanced bacterial binding by innate immune cells from children with |
| 436 | SAM relative to healthy controls is not solely due to their complications/comorbidities and |
| 437 | may reflect as-yet-uncharacterized immune activating/regulatory processes specific to SAM. |
| 438 | However, our data also demonstrate the relevance of demographic and clinical heterogeneity |
| 439 | in children with SAM for other aspects of anti-bacterial innate immune cell function. PC2 |
| 440 | was positively associated with MUAC, which reflects findings from a recent study among |
| 441 | children admitted to hospitals in Kenya and Uganda with all-cause critical illness (46.0% |
| 442 | were severely wasted). In that study, LPS-induced whole blood pro-inflammatory cytokine |
| 443 | responses, including IL-6, IL-8 and $TNF\alpha$, were lower among hospitalized versus healthy |
| 444 | children in unadjusted analyses; this relationship was reversed after adjustment for |
| 445 | MUAC(38), indicative of a distinct pattern of LPS-induced responses among wasted children. |
| 446 | HIV profoundly impacts monocyte composition, trafficking and function, including |
| 447 | maturation of monocytes into intermediate and non-classical sub-sets(48), circulating |
| 448 | numbers due to increased homing to the gut(49), and release of sCD14 into circulation(50). |
| 449 | HIV is also associated with the non-edematous form of SAM, a more severe pattern of |
| 450 | wasting, increased risk of opportunistic infections, and HIV-driven inflammation is a risk |

Phiri et al, preprint

| 451 | factor for hospitalization with SAM among children living with HIV in LMIC(36, 51, 52). |
|-----|---|
| 452 | Consistent with HIV having an impact on the interrelationship between nutritional status and |
| 453 | innate immune cell function, we found that excluding children with HIV strengthened the |
| 454 | effect of SAM status on PC1 and PC5 in sensitivity analyses. HIV-SAM was also associated |
| 455 | with lower monocyte activation in response to bacterial PAMP (PC3) than SAM alone. PC4 |
| 456 | scores were lowest in the youngest age group suggesting that these children were less able to |
| 457 | release MPO, an enzyme which catalyzes oxidative burst that is most abundantly expressed in |
| 458 | neutrophil granules, upon bacterial PAMP stimulation. All children with SAM had higher |
| 459 | basal MPO levels in unstimulated culture supernatants compared to healthy controls but basal |
| 460 | levels were highest among children with SAM in the youngest age group (Figure S7), |
| 461 | indicating that they had higher systemic oxidative stress and neutrophil degranulation relative |
| 462 | to children in the older 2 age groups. Pre-exposure of monocytes from healthy adults to LPS |
| 463 | in vitro (n=2) impairs their cytokine release, oxidative burst and pathogen killing compared |
| 464 | to saline-treated monocytes $(n=3)(53)$. Thus, whilst higher basal levels of MPO may promote |
| 465 | pathogen killing by young children with SAM in the short-term, subsequent deficits in pre- |
| 466 | formed MPO granules and capacity for MPO release by granulocytes may compromise their |
| 467 | defense against infections in the longer term (53) . |
| | |

468

We did not find evidence that coincident symptoms of infection influenced any of the immune function PCs. This was an unexpected finding given that acute infections expand and prime immune cells *in vivo* and 60.0% of our cohort had at least 1 symptom of infection at the time of immune function assessment. However, since we were reliant on physician examination-based identification of infections per standard of care at the hospital recruitment sites, our data likely underestimated the prevalence of infections. It is also plausible that reduced cytokine production and monocyte activation marker expression in response to

Phiri et al, preprint

| 476 | bacterial PAMP might mask infectious symptoms in children with SAM. Inclusion of |
|-----|--|
| 477 | molecular diagnostics in future studies would provide greater scope to characterize the impact |
| 478 | of concurrent infections and specific pathogens on SAM immune function. |
| 479 | |
| 480 | Nutritional rehabilitation after hospital admission relies on resolution of clinical |
| 481 | complications alongside therapeutic re-feeding; an outstanding question which we are |
| 482 | pursuing using longitudinal samples from this cohort during post-discharge follow-up, is |
| 483 | whether or not rehabilitation of immune cell function accords with anthropometric |
| 484 | recovery(36). Cross-sectional evaluation during inpatient rehabilitation demonstrated that |
| 485 | bacterial binding (PC1) and neutrophil responses (PC5) were negatively associated with the |
| 486 | duration between hospital admission and immune function assessment. High scores for PC1 |
| 487 | and PC5 differentiated children with SAM from healthy controls, therefore their negative |
| 488 | relationship with inpatient treatment duration in the SAM group is indicative of these |
| 489 | responses 'normalizing' towards those seen in healthy immune cells. This has previously |
| 490 | been suggested in pilot studies of blood immune cell function $(n=10)(54)$, and for circulating |
| 491 | dendritic cells from children hospitalized with SAM in Zambia which were higher in number, |
| 492 | LPS-induced HLA-DR expression, and unstimulated IL-12 secretion at discharge than at |
| 493 | hospital admission (n=27)(41). Normalization of innate immune cell function towards that |
| 494 | seen in healthy children could reflect and contribute to resolution of other physiological |
| 495 | features disrupted in complicated SAM and posited as drivers of systemic inflammation (e.g. |
| 496 | dysbiosis, metabolic profiles, gut barrier function)(26, 55-57). For example, pro- |
| 497 | inflammatory biomarkers that discriminated between the plasma proteome of 30 children |
| 498 | with SAM and 21 healthy children in Bangladesh normalized following 4 weeks of a |
| 499 | microbiota-directed legume-based feeding intervention in concert with increased WHZ and |
| 500 | microbiota maturity(55). The 'immune rehabilitation' of anti-bacterial responses was |
| | |

Phiri et al, preprint

| 501 | incomplete in our cohort of SAM inpatients since all but 9/126 (7.1%) had PC1 scores greater |
|-----|--|
| 502 | than the median score for the healthy group. Functional indicators of monocyte activation and |
| 503 | mediator secretion in response to PAMP (PC2-4) were unaffected by time to immune assay, |
| 504 | consistent with their stronger association with more stable participant characteristics (age |
| 505 | group, HIV status) and continuous relationship with MUAC rather than with SAM status. |
| 506 | |
| 507 | The clinical importance of normalizing anti-bacterial innate immune cell function as part of |
| 508 | rehabilitation from SAM is supported by evidence that PC1 scores during hospitalization were |
| 509 | associated with persistent SAM status at discharge, a predictor of both mortality and persistent |
| 510 | wasting over a year of post-discharge follow-up in HOPE-SAM(6, 9). Scores for PC3 |
| 511 | (monocyte activation), which tended to be lower in children with SAM than healthy controls, |
| 512 | were associated with higher odds of persistent wasting within the SAM group. Given the |
| 513 | energetic cost of monocyte activation and turnover(58), which is associated with changes in |
| 514 | circulating lipid levels(58), it is plausible that heightened pro-inflammatory capacity of blood |
| 515 | monocytes might benefit anti-bacterial defense but compromise weight gain in children |
| 516 | recovering from SAM. The association between immune cell function and wasting that we |

recovering from SAM. The association between immune cell function and wasting that we identified accords with evidence from HIV-negative children recovering from SAM in Kenya for whom MUAC and WHZ gains over the first 60 days post-discharge were negatively associated with circulating biomarkers of systemic inflammation(*56*).

520

521 Whilst this study advances our understanding of immune function in SAM, our data should 522 be interpreted in the context of several limitations. Firstly, our cohort included only children 523 able to provide a $\geq 2mL$ blood sample, necessarily excluding the most acutely unwell children 524 and those who died prior to enrolment or blood sampling; our findings are therefore most 525 applicable to children who survive to hospital discharge. Second, we undertook immune

Phiri et al, preprint

function assessment across a range of time-points after hospital admission which contributed 526 to immune heterogeneity in the SAM group. Adjusting analyses for time to immunoassay, 527 presenting cross-sectional analyses of PCs by time to immunoassay and sensitivity analyses 528 focusing on children for whom immune function was assessed prior to the day of discharge, 529 go some way to demonstrate the effect of this variable on our findings and the 530 generalizability of the SAM-related differences that we see despite this limitation. Thirdly, 531 there remains much to learn about the immunobiology of SAM(24, 34), much of which was 532 not possible to explore in this study but would be pertinent to our interpretation. We chose to 533 534 focus on gram-negative bacterial PAMP which are among the most common clinical isolates from children with SAM but unlikely to be the only group of infections nor LPS the only 535 PAMP translocated in the context of SAM; in our cohort alone, 11.5% of the SAM group had 536 537 fungal infections (oral candidiasis) and 13.8% tuberculosis at the time of their immunoassay, and gram-positive bacteria, viruses, fungi and parasites are also prevalent in undernourished 538 children(10, 15). Similarly, SAM is implicated in impaired adaptive immunity (33, 59), and, 539 although we provide some evidence for bulk differences in bacterial binding by Lin+ 540 lymphocyte populations in children with SAM, detailed analyses of adaptive immunity was 541 beyond our scope. Fourth, though our study is the largest of its kind and adequately-powered 542 for our primary comparison between the SAM and healthy groups, it is increasingly apparent 543 from clinical studies of SAM, including our own(6, 9, 51), that specific co-morbidities 544 545 contribute to sub-conditions within current SAM diagnostic criteria (e.g. HIV-SAM, cerebral palsy-SAM, edematous/non-edematous SAM); a larger or comorbidity-focused sample size 546 would be required to conclusively evaluate the impact of these variables on immune function. 547 Since some of these comorbidities are shared by hospitalized children without SAM and 548 recent studies suggest that these children have distinct anti-bacterial pro-inflammatory 549

Phiri et al, preprint

| 550 | mediator responses relative to healthy controls to those we observe in SAM(38), it would be |
|-----|---|
| 551 | desirable to include such children as an additional comparison group in future studies. |

552

553 Overall, we provide evidence for a functional shift in how innate immune cells respond to bacterial PAMP during hospitalization with complicated SAM, with enhanced bacterial 554 binding capacity of monocytes and neutrophils differentiating children with SAM from healthy 555 controls alongside characteristics of impaired monocyte maturation and pro-inflammatory 556 cytokine secretion to bacterial PAMP. Differences in bacterial binding capacity are not 557 558 explained by patient demography or clinical comorbidities, but are more tractable to inpatient treatment than other domains of innate immune function and contribute to persistent SAM at 559 discharge; a predictor of mortality and poor nutritional recovery after hospital discharge(6, 9). 560 Thus, innate immune cells from children with SAM strike a balance in their response to new 561 infectious challenges, which impacts inpatient rehabilitation and may contribute to persistent 562 health deficits after hospital discharge. 563

564

565 MATERIALS AND METHODS

566 Study design

IMMUNe function Of children with SAM (IMMUNO-SAM) is a translational immunology 567 study designed to characterize anti-bacterial innate immune cell function using blood samples 568 569 from children under 5 years old hospitalized with complicated SAM at three tertiary referral hospitals in Lusaka (University Teaching Hospital), Zambia and Harare (Harare Central 570 Hospital and Parirenyatwa Hospital), Zimbabwe. All participants were enrolled into Health 571 Outcomes and PathogEnesis of SAM (HOPE-SAM), a longitudinal observational study for 572 which the primary outcome was mortality over 1 year of post-discharge follow-up; clinical 573 study protocols and outcomes are published elsewhere (6, 9, 36, 60). 574

Phiri et al, preprint

| 5 | 7 | 5 |
|---|---|---|
| Э | 1 | Э |

Ethical approval was obtained from the University of Zambia Biomedical Research Ethics 576 Committee, and the Medical Research Council of Zimbabwe. The ethics committee of the 577 Queen Mary University of London provided an advisory review. Caregivers of all 578 participants provided written informed consent for their participation. 579 580 **Study participants** 581 SAM cases were children aged 0-59 months, admitted to one of the three hospital sites with 582 complicated SAM. SAM was diagnosed according to the current WHO definition as 583 WHZ <-3, MUAC <115 mm and/or the presence of nutritional edema for children above 6 584 months of age, or WHZ ≤ -3 and/or nutritional edema for those aged under 6 months(1). 585 *Healthy controls* were children aged 6-59 months who were adequately-nourished (WHZ >--586 1) and clinically well (no symptoms of acute illness or current infections). Additional 587 inclusion criteria were: 1) enrolled into HOPE-SAM after ethical approval of IMMUNO-588 SAM procedures (August 2017); 2) known HIV status; 3) \geq 2mL blood sample collected 589 during hospitalization (SAM group) or at baseline visit (healthy controls); and, 4) no 590 underlying chronic gastrointestinal disease or a known malignancy. For SAM cases, any 591 blood sample collected between their initial clinical assessment at baseline and their 592 discharge from hospital was admissible to the study. Age groups were pre-specified for the 593 594 HOPE-SAM study (0-5 mo, 6-11 mo, 12-23 mo and 24-59 mo)(36); the 7 children in the SAM group who were aged under 6 mo at admission were included in the youngest age group 595 (0-11 mo). 596

597

598 Clinical procedures

Phiri et al, preprint

| 599 | Clinical, household and demographic characteristics from the primary caregiver of each child |
|-----|--|
| 600 | via questionnaire at study baseline, i.e. as soon as possible after hospital admission. Clinical |
| 601 | care for SAM cases was implemented according to country-specific guidelines based on |
| 602 | WHO guidelines $(1, 2)$. Where HIV status could not be confirmed by the clinical team, HIV |
| 603 | status for mothers and for children aged >18mo was determined by the HOPE-SAM study |
| 604 | team using a rapid antibody test algorithm, and for children <18mo using HIV DNA PCR. |
| 605 | Daily clinical review of each child with SAM was undertaken by a study physician using a |
| 606 | standardized inpatient review form. Anthropometry was conducted at baseline and repeated |
| 607 | for SAM cases on the day of discharge. Weight was recorded to the nearest 10g using a |
| 608 | Seca384 electronic scale for infants and to the nearest 100g using a Seca874 electronic scale |
| 609 | for older children. MUAC was recorded to the nearest 1mm using WHO/UNICEF MUAC |
| 610 | tape. Length/height were measured to the nearest 0.1cm using UNICEF measuring boards. |
| 611 | |
| 612 | Children were discharged to outpatient community-based management of nutritional |
| 613 | rehabilitation according to WHO-adapted country guidelines, which specify that discharge is |
| 614 | appropriate when a child's medical complications, including edema, are resolving, they are |
| 615 | clinically well, alert and their appetite has returned $(1, 2)$. |
| 616 | |
| 617 | Blood sample collection |
| 618 | Blood samples (1 mL/kg up to a maximum of 5.4 mL) were collected into endotoxin-free |
| 619 | EDTA-treated blood collection tubes. Blood was not collected from children with severe |

620 anemia (known hemoglobin <60 g/L).

621

622 Bacterial binding assay

| 623 | On the day of blood sample collection, 100ul of undiluted whole blood was added to pre- |
|-----|--|
| 624 | prepared cryovials with: culture media only (RPMI 1640 medium supplemented with 1% v/v |
| 625 | penicillin-streptomycin; unstimulated control), and 5×10^5 AF488-conjugated <i>E. coli</i> |
| 626 | bioparticles diluted in culture medium. Cultures were mixed thoroughly and incubated for 1h |
| 627 | at 37°C, 6% CO ₂ using the CO2Gen compact system. After 1h, cultured cells were treated |
| 628 | with 1x FACS lysing and fixative buffer for 10mins, washed in phosphate-buffered saline |
| 629 | (PBS), resuspended in cell freezing medium (PBS with 10% v/v dimethyl sulfoxide (DMSO), |
| 630 | 40% v/v heat-inactivated fetal bovine serum (FBS)), and gradually frozen overnight at |
| 631 | 1°C/min to -80°C using a Mr. Frosty freezing container. Details of key reagents are provided |
| 632 | in Table S12. |
| 633 | |
| 634 | Whole blood cultures |
| 635 | On the day of blood sample collection, 750ul of whole blood was diluted in 1.45mL culture |
| 636 | media. 500ul/well of diluted blood was added to wells of pre-prepared 48-well culture plates |
| 637 | containing culture media alone (unstimulated control), HKST (final concentration: |
| 638 | 1x10 ⁸ cells/mL) and ultrapure <i>E. coli</i> LPS (final concentration: 0.25EU/mL). Whole blood |
| 639 | cultures were incubated for 24h at 37°C, 6% CO ₂ using the CO2Gen compact system. Cell- |
| 640 | free culture supernatants were harvested and cryopreserved at -80°C. Cultured blood cells |
| 641 | were subjected to red blood cell lysis, fixed and cryopreserved, as above. Details of key |
| 642 | reagents are provided in Table S12 |
| 643 | |
| 644 | Plasma, stool and culture supernatant ELISA |
| 645 | Biomarkers of systemic inflammation (C-reactive protein (CRP), monocyte/macrophage |
| 646 | activation (soluble CD14 (sCD14), sCD163) and LPS-binding protein (LBP) were quantified |
| 647 | in plasma (Biotechne Quantikine ELISA kits) and myeloperoxidase (MPO; Immundianostik, |

| 648 | Bensheim, Germany) and neopterin (GenWay Biotech Inc, San Diego, CA, USA) in stool via |
|-----|---|
| 649 | ELISA at Zvitambo and TROPGAN laboratories; methods previously reported(6, 9, 36). |
| 650 | |
| 651 | TNF α , IL-6, IL-8 and MPO concentrations were quantified in whole blood culture |
| 652 | supernatants by ELISA (reagent details in Table S12) at Zvitambo and TROPGAN |
| 653 | laboratories. ELISA lower limits of detection were: TNF α - 15.6pg/ml, IL-6 - 4pg/ml, IL-8 - |
| 654 | 31.2pg/ml and MPO - 62.5pg/ml. Concentrations below the assay detection limit were |
| 655 | censored at the limit of detection; those greater than the top standard concentration were re- |
| 656 | run at higher dilution and multiplied by the dilution factor. |
| 657 | |
| 658 | Flow cytometry |
| 659 | Cryopreserved bacterial binding assay cell samples were labelled with the following |
| 660 | fluorochrome-labelled antibody panel: Lin (CD3, CD19, CD20, CD56)-APC, CD66b- |
| 661 | PerCPCy5.5, CD16-APCCy7, HLA-DR-PECy7, CD14-PE; Table S12) to identify which cell |
| 662 | types were bound to the AF488-labelled E. coli-coated bioparticles. Cryopreserved whole |
| 663 | blood culture cell samples were labelled with the following fluorochrome-labelled antibody |
| 664 | panel: Lin (CD3, CD19, CD20, CD56)-APC, CD66b-APC, CD16-APCCy7, HLA-DR- |
| 665 | PECy7, CD14-PE, CD86-FITC, CD40-PerCPCy5.5; Table S12). Flow cytometry was |
| 666 | conducted on the day of antibody labelling using 6-colour BD Biosciences FACSVerse |
| 667 | cytometers (488nm and 633nm lasers) at Zvitambo and TROPGAN laboratories after daily |
| 668 | instrument calibration using CS&T beads and the Performance QC program in FACSuite |
| 669 | software. Flow cytometry gating strategies (Figure S2) were implemented in FlowJo version |
| 670 | 10.8.1 (FlowJo, LLC, USA); universal gates were based on fluorescence-minus-one controls for |
| 671 | each marker, applied to all samples, and adjusted per participant based on their corresponding |
| 672 | assay-specific unstimulated control sample. |
| | |

Phiri et al, preprint

673

674 Statistical Analyses

Proportional data were analyzed by fractional regression, mean (*E. coli*-AF488) and median
(HLA-DR, CD86 and CD40) fluorescence intensity (FI) data were left-censored at 1 and
analyzed by tobit regression after log-transformation, and, soluble mediator concentrations in
culture supernatants were left-censored at the assay limit of detection and analyzed by tobit
regression after log-transformation.

680

LPS- and HKST-induced median fluorescence intensities (HLA-DR, CD86 and CD40) and 681 soluble mediator concentrations were calculated for each participant by subtracting values for 682 their corresponding unstimulated cultures, left-censored at 0 (i.e. no detectable response 683 above that in unstimulated cultures). There was no background meanFI or proportions of E. 684 coli+ cells in unstimulated cultures, these were uncensored. The effect of SAM status on log-685 transformed proportions of E. coli+ cells was analyzed by fractional regression, on log-686 transformed LPS- and HKST-induced monocyte medianFI (HLA-DR, CD86 and CD40) and 687 log-transformed LPS- and HKST-induced supernatant mediator concentrations by tobit 688 regression, and on log-transformed E. coli-AF488 meanFI by linear regression. tSNE plots 689 for all compensated cell surface markers (Lin, CD14, CD16, CD66b, HLA-DR) were 690 generated for 500 E. coli+ leukocytes events per participant for all SAM cases and healthy 691 692 controls and FlowSOM analysis applied using the cytofkit2 package in R. 693

Log-transformed PAMP-induced innate immune cell function outcome measures for all SAM cases (n=126) and healthy controls (n=73) with complete data were standardized (mean=0, standard deviation=1) and entered into a single principal components analysis. Resulting principal components (PCs) with an eigenvalue >1 and \geq 1 of the original variables loading

| 698 | onto the PC with a factor loading $\geq \pm 0.3$ were selected for subsequent analyses. The effect of |
|-----|---|
| 699 | SAM status on immune profiles (PC1-5 scores) was analyzed by linear regression before and |
| 700 | after adjusting for age group, sex, HIV status, hospital site and immune function assessment |
| 701 | on the day of discharge. Variables were selected for inclusion in adjusted model based on |
| 702 | causal inference methodology using a directed acyclic graph (DAG) of exposure and outcome |
| 703 | measures generated using Daggity software(61) (Figure S8A). We undertook pre-specified |
| 704 | sensitivity analyses excluding: 1) HIV-positive participants and 2) participants for whom |
| 705 | immune function was assessed on the same day as discharge. |
| 706 | |
| 707 | The effects of clinically-relevant demographic and clinical characteristics on anti-bacterial |
| 708 | innate immune function were estimated for each PC using cross-fit partialling-out lasso linear |
| 709 | regression with default lambda selection. Sex, hospital site, time to immunoassay, baseline |
| 710 | WHZ, baseline HAZ, birthweight and cerebral palsy status were offered as control variables |
| 711 | based on their putative contribution to variation in both immune function and clinical |
| 712 | outcomes (Figure S8B). |
| 713 | |
| 714 | To characterize the cross-sectional relationship between immune function and duration of |
| 715 | hospitalization, we analyzed PC1-5 scores by time to immunoassay via linear regression, |
| 716 | adjusting for hospital site, symptoms of infection on the day of immune function assessment |
| 717 | and immune function assessment on the day of discharge (Figure S8C). |
| 718 | |
| 719 | We tested the effect of immune function assessed prior to the day of discharge on SAM status |
| 720 | at discharge via logistic regression, adjusting for sex, baseline age group, HIV status, hospital |
| 721 | site, time to immunoassay, and baseline MUAC (Figure S8D). Children discharged against |
| 722 | medical advice were excluded from these analyses. |

Phiri et al, preprint

- All statistical analyses were performed using STATA version 17 (StataCorp LLC, USA).
- 725 Outcome variables were plotted using Prism version 9 (GraphPad Software Inc., USA) and R
- version 4.2.0.
- 727

Phiri et al, preprint

728 **REFERENCES**

729 WHO, in Guideline: Updates on the management of severe acute malnutrition in 730 1. infants and children. (World Health Organization 731 Copyright © World Health Organization 2013., Geneva, 2013). 732 G. WHO, Management of the child with a serious infection or severe malnutrition: 733 2. 734 guidelines for care at the first-referral level in developing countries. (2000). R. Karunaratne, J. P. Sturgeon, R. Patel, A. J. Prendergast, Predictors of inpatient 735 3. mortality among children hospitalized for severe acute malnutrition: a systematic 736 review and meta-analysis. The American journal of clinical nutrition, (2020). 737 4. UNICEF, WHO, W. Bank, "Levels and trends in child malnutrition: 738 UNICEF/WHO/The World Bank Group joint child malnutrition estimates: key 739 findings of the 2021 edition," (2021). 740 D. Sharrow *et al.*, Global, regional, and national trends in under-5 mortality between 5. 741 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by 742 the UN Inter-agency Group for Child Mortality Estimation. The Lancet Global Health 743 744 10, e195-e206 (2022). 6. M. Bwakura-Dangarembizi *et al.*, Recovery of children following hospitalisation for 745 complicated severe acute malnutrition. Maternal & Child Nutrition 18, e13302 746 (2022). 747 7. M. Kerac et al., Follow-up of post-discharge growth and mortality after treatment for 748 severe acute malnutrition (FuSAM study): a prospective cohort study. PLOS ONE 9, 749 750 e96030 (2014). A. Talbert et al., Diarrhoea complicating severe acute malnutrition in Kenyan 8. 751 children: a prospective descriptive study of risk factors and outcome. PLOS ONE 7, 752 753 e38321 (2012). 9. M. Bwakura-Dangarembizi et al., Risk factors for postdischarge mortality following 754 hospitalization for severe acute malnutrition in Zimbabwe and Zambia. The American 755 journal of clinical nutrition 113, 665-674 (2021). 756 10. J. A. Berkley *et al.*, Daily co-trimoxazole prophylaxis to prevent mortality in children 757 with complicated severe acute malnutrition: a multicentre, double-blind, randomised 758 placebo-controlled trial. The Lancet. Global health 4, e464-473 (2016). 759 11. M. Ngari *et al.*, Mortality during and following hospital admission among school-760 aged children: a cohort study. Wellcome Open Research 5, 234 (2021). 761 M. M. Ngari et al., Changes in susceptibility to life-threatening infections after 12. 762 763 treatment for complicated severe malnutrition in Kenya. The American journal of *clinical nutrition* **107**, 626-634 (2018). 764 13. J. A. Berkley et al., Bacteremia among children admitted to a rural hospital in Kenya. 765 766 N Engl J Med 352, 39-47 (2005). 14. A. L. Page et al., Infections in children admitted with complicated severe acute 767 malnutrition in Niger. PLoS One 8, e68699 (2013). 768 15. S. Attia *et al.*, Mortality in children with complicated severe acute malnutrition is 769 related to intestinal and systemic inflammation: an observational cohort study. The 770 American journal of clinical nutrition 104, 1441-1449 (2016). 771 772 16. K. Maitland *et al.*, Children with severe malnutrition: can those at highest risk of death be identified with the WHO protocol? PLOS Medicine 3, e500 (2006). 773 I. Olofin et al., Associations of suboptimal growth with all-cause and cause-specific 17. 774 775 mortality in children under five years: a pooled analysis of ten prospective studies. PLoS One 8, e64636 (2013). 776

| 777 | 18. | B. Amadi et al., Adaptation of the small intestine to microbial enteropathogens in |
|-----|------|---|
| 778 | | Zambian children with stunting. <i>Nature Microbiology</i> 6 , 445-454 (2021). |
| 779 | 19. | S. Mero et al., Prevalence of diarrhoeal pathogens among children under five years of |
| 780 | | age with and without diarrhoea in Guinea-Bissau. PLoS Neglected Tropical Diseases |
| 781 | | 15 , e0009709 (2021). |
| 782 | 20. | G. Patterson et al., Environmental, metabolic, and inflammatory factors converge in |
| 783 | | the pathogenesis of moderate acute malnutrition in children: an observational cohort |
| 784 | | study. The American Journal of Tropical Medicine and Hygiene, (2021). |
| 785 | 21. | J. Lauer <i>et al.</i> , Markers of environmental enteric dysfunction are associated with poor |
| 786 | | growth and iron status in rural ugandan infants. <i>The Journal of nutrition</i> 150 , (2020). |
| 787 | 22. | S. Sved <i>et al.</i> , Serum anti-flagellin and anti-lipopolysaccharide immunoglobulins as |
| 788 | | predictors of linear growth faltering in Pakistani infants at risk for environmental |
| 789 | | enteric dysfunction <i>PLoS ONE</i> 13 e0193768 (2018) |
| 790 | 23 | K D I Jones <i>et al.</i> Mesalazine in the initial management of severely acutely |
| 791 | 23. | malnourished children with environmental enteric dysfunction: a pilot randomized |
| 792 | | controlled trial <i>BMC Medicine</i> 12 , 133 (2014) |
| 793 | 24 | C D Bourke I A Berkley A I Prendergast Immune Dysfunction as a Cause and |
| 704 | Δ-τ. | Consequence of Malnutrition Trends in Immunology 37 386-398 (2016) |
| 705 | 25 | I M Niunge <i>et al.</i> Biomarkers of post-discharge mortality among children with |
| 796 | 25. | complicated severe acute malnutrition Scientific Reports 9 5981 (2019) |
| 790 | 26 | B Wen at al. Systemic inflammation and metabolic disturbances underlie inpatient |
| 709 | 20. | b. Wen et u., Systemic inflammation and inclusione disturbances underne inplatent mortality among ill children with severe malnutrition. Science Advances 8, eshi6770 |
| 790 | | (2022) |
| /99 | 27 | (2022). I. N. Sheleye <i>et al.</i> Human managetee undergo functional reprogramming during |
| 800 | 21. | 1. N. Shalova <i>et al.</i> , Human monocytes undergo functional re-programming during sensis mediated by hypervis indusible factor Jalpha <i>Lymunity</i> 42 , 484, 408 (2015) |
| 801 | 20 | D. M. da Azambuja Badriguas et al. Protoomias reveals disturbances in the immuno |
| 802 | 28. | P. M. de Azambuja Rodrigues <i>et al.</i> , Proteonnes revears disturbances in the infinute |
| 803 | | <i>P</i> == 11, 15140 (2021) |
| 804 | 20 | Rep 11, 15149 (2021). |
| 805 | 29. | 1. Akoumianaki <i>et al.</i> , Uncoupling of IL-6 signaling and LC3-associated |
| 806 | | phagocytosis drives immunoparalysis during sepsis. Cell Host & Microbe 29, 12//- |
| 807 | 20 | 1293.e12/6 (2021). |
| 808 | 30. | SC. Cheng <i>et al.</i> , Broad defects in the energy metabolism of leukocytes underlie |
| 809 | 01 | immunoparalysis in sepsis. Nat Immunol 17, 406-413 (2016). |
| 810 | 31. | J. Leentjens <i>et al.</i> , Reversal of immunoparalysis in humans in vivo. <i>American Journal</i> |
| 811 | | of Respiratory and Critical Care Medicine 186 , 838-845 (2012). |
| 812 | 32. | G. Monneret <i>et al.</i> , Marked elevation of human circulating $CD4 + CD25 +$ regulatory |
| 813 | | T cells in sepsis-induced immunoparalysis. Crit Care Med. 31, (2003). |
| 814 | 33. | M. J. Rytter, L. Kolte, A. Briend, H. Friis, V. B. Christensen, The immune system in |
| 815 | | children with malnutrition - a systematic review. <i>PLoS ONE</i> 9, e105017 (2014). |
| 816 | 34. | C. D. Bourke, K. D. J. Jones, A. J. Prendergast, Current understanding of innate |
| 817 | | immune cell dysfunction in childhood undernutrition. <i>Frontiers in Immunology</i> 10 , |
| 818 | | (2019). |
| 819 | 35. | AL. Page <i>et al.</i> , Infections in children admitted with complicated severe acute |
| 820 | | malnutrition in Niger. PLOS ONE 8, e68699 (2013). |
| 821 | 36. | M. Bwakura-Dangarembizi et al., Health outcomes, pathogenesis and epidemiology |
| 822 | | of severe acute malnutrition (HOPE-SAM): rationale and methods of a longitudinal |
| 823 | | observational study. BMJ Open 9, e023077 (2019). |
| 824 | 37. | A. A. Patel et al., The fate and lifespan of human monocyte subsets in steady state and |
| 825 | | systemic inflammation. The Journal of Experimental Medicine 214, 1913-1923 |
| 826 | | (2017). |

| 827 | 38. | L. S. Uebelhoer <i>et al.</i> , Toll-like receptor-induced immune responses during early |
|------------|------------|---|
| 828 | | childhood and their associations with clinical outcomes following acute illness among |
| 829 | | infants in sub-Saharan Africa. Frontiers in Immunology 12, (2022). |
| 830 | 39. | T. F. Manzoli <i>et al.</i> , Lymphocyte count as a sign of immunoparalysis and its |
| 831 | | correlation with nutritional status in pediatric intensive care patients with sepsis: A |
| 832 | | pilot study. <i>Clinics (Sao Paulo Brazil)</i> 71 , 644-649 (2016) |
| 833 | 40 | M W Hall <i>et al.</i> Immunoparalysis and nosocomial infection in children with |
| 834 | 10. | multiple organ dysfunction syndrome Intensive Care Med 37 525-532 (2011) |
| 835 | <i>4</i> 1 | S M Hughes <i>et al.</i> Dendritic cell anergy results from endotoxemia in severe |
| 836 | 71. | malnutrition The Journal of Immunology 183, 2818-2826 (2009) |
| 837 | 42 | S Gordon Phagocytosis: an immunobiologic process <i>Immunity</i> 44 463-475 (2016) |
| 838 | 42. 43 | R S Jack II Grunwald F Stelter G Workalemahu C Schütt Both membrane- |
| 830 | чэ. | hound and soluble forms of CD14 bind to gram-negative bacteria. European journal |
| 840 | | of immunology 25 1/36-1//1 (1005) |
| 840 841 | 11 | U Grunwald at al Monocytes can phagocytose Gram negative bacteria by a CD14 |
| 842 | | dependent mechanism <i>Limmunol</i> 157 A110-A125 (1006) |
| 042 942 | 15 | E A Frey at al. Soluble CD14 participates in the response of colls to |
| 045 044 | 43. | L. A. Hey et al., Soluble CD14 participates in the response of certs to |
| 844 | 16 | E Operio et al. Molautation related perceite discontingtion from the chin in visconal |
| 845 | 40. | E. Osorio <i>et al.</i> , Mainutrition-related parasite dissemination from the skin in visceral |
| 846 | | reisnmaniasis is driven by PGE2-mediated amplification of CCR /-related trafficking |
| 847 | | of infected inflammatory monocytes. PLos Neglected Tropical Diseases 17, |
| 848 | 47 | e0011040 (2023). |
| 849 | 47. | K. Leventogiannis <i>et al.</i> , Toward personalized immunotherapy in sepsis: The |
| 850 | 1.0 | PROVIDE randomized clinical trial. <i>Cell Reports Medicine</i> 3 , (2022). |
| 851 | 48. | P. Chen <i>et al.</i> , Perturbations of monocyte subsets and their association with T helper |
| 852 | | cell differentiation in acute and chronic HIV-1-infected patients. Frontiers in |
| 853 | | Immunology 8, 272 (2017). |
| 854 | 49. | K. Allers <i>et al.</i> , Macrophages accumulate in the gut mucosa of untreated HIV-infected |
| 855 | | patients. <i>The Journal of Infectious Diseases</i> 209 , 739-748 (2013). |
| 856 | 50. | A. J. Prendergast <i>et al.</i> , Intestinal damage and inflammatory biomarkers in Human |
| 857 | | Immunodeficiency Virus (HIV)-exposed and HIV-infected Zimbabwean infants. The |
| 858 | | Journal of Infectious Diseases 216, 651-661 (2017). |
| 859 | 51. | A. Prendergast et al., Hospitalization for severe malnutrition among HIV-infected |
| 860 | | children starting antiretroviral therapy. AIDS (London, England) 25, 951-956 (2011). |
| 861 | 52. | A. J. Prendergast et al., Inflammatory biomarkers in HIV-infected children |
| 862 | | hospitalized for severe malnutrition in Uganda and Zimbabwe. AIDS (London, |
| 863 | | <i>England</i>) 33 , 1485-1490 (2019). |
| 864 | 53. | I. Grondman et al., Endotoxin-induced immunotolerance is associated with loss of |
| 865 | | monocyte metabolic plasticity and reduction of oxidative burst. <i>Journal of Leukocyte</i> |
| 866 | | Biology 106, (2019). |
| 867 | 54. | R. Peixoto Paes-Silva, M. Correia de Macedo É, M. T. Oliveira Tomiva, C. M. |
| 868 | | Machado Barbosa de Castro. Immune respose of severe malnutrition children treated |
| 869 | | according to the protocol of the World Health Organisation. <i>Nutricion hospitalaria</i> |
| 870 | | 32 638-644 (2015). |
| 871 | 55 | L. L. Gehrig <i>et al.</i> Effects of microbiota-directed foods in gnotobiotic animals and |
| 872 | 55. | undernourished children Science 365 (2019) |
| 873 | 56 | I Niunge <i>et al.</i> Systemic inflammation is negatively associated with early post |
| 87/ | 50. | discharge growth following acute illness among severely malnourished children - a |
| 875 | | nilot study Wellcome Open Research 5 248 (2021) |
| 015 | | phototady. $memory open Research 5, 270 (2021).$ |

- N. Calder *et al.*, Modifying gut integrity and microbiome in children with severe acute
 malnutrition using legume-based feeds (MIMBLE): A pilot trial. *Cell reports. Medicine* 2, 100280 (2021).
 V. K. Patal, H. Williama, S. C. H. Li, L. P. Flatabar, H. L. Madhurry, Managuta
- 58. V. K. Patel, H. Williams, S. C. H. Li, J. P. Fletcher, H. J. Medbury, Monocyte
 inflammatory profile is specific for individuals and associated with altered blood lipid
 levels. *Atherosclerosis* 263, 15-23 (2017).
- N. Nabukeera *et al.*, Thymus size and its correlates among children admitted with
 severe acute malnutrition: a cross-sectional study in Uganda. *BMC Pediatrics* 21,
 (2021).
- M. Bwakura-Dangarembizi *et al.*, Fat and lean mass predict time to hospital
 readmission or mortality in children treated for complicated severe acute malnutrition
 in Zimbabwe and Zambia. *The British journal of nutrition*, 1-25 (2022).
- B. J. Textor, B. van der Zander, M. K. Gilthorpe, M. Liskiewicz, G. T. H. Ellison,
 Robust causal inference using directed acyclic graphs: the R package 'dagitty'. *International Journal of Epidemiology* 45, 1887-1894 (2016).
- 891 892

Phiri et al, preprint

893 ACKNOWLEDGMENTS

- 894 We thank all the caregivers and children who participated in the HOPE-SAM study and the
- staff at Harare Central Hospital, Parirenyatwa Hospital and the University Teaching Hospital
- for hosting the study team. We acknowledge the wider HOPE-SAM study team (members
- listed here: <u>https://bmjopen.bmj.com/content/9/1/e023077</u>) and Stephen Moyo (logistics),
- 898 Philippa Rambanepasi (finance), Virginia Sauramba and Miyoba Chipunza (compliance), and
- Agatha Muyenga (administration), in particular, for their additional support for this study at
- 900 Zvitambo and TROPGAN. We acknowledge Emma Chambers for initial support with tSNE.
- 901

902 FUNDING

- 903 IMMUNO-SAM was funded by:
- Joint Wellcome Trust and the Royal Society, UK grant 206225/Z/17/Z to CDB
- 905 HOPE-SAM was funded by:
- 906 Medical Research Council, UK grant MR/K012711/1
- 907 Wellcome Trust grants 107634/Z/15/Z to MB, 220566/Z/20/Z and 108065/Z/15/Z to AJP
- 908 UNICEF Zimbabwe grant ZIM/PCA201721/PD2019158

909

910 AUTHOR CONTRIBUTIONS

- 911 Implementation of laboratory work: TNP, SR, MG, PM, SM, TH, TR, LC, CDB
- 912 Laboratory management: KM, KZ
- 913 Data processing: CDD, JT, CDB, JPS, RCR, MB
- 914 Data management: RN
- 915 Clinical data collection: MB, FDM, DN, KC, CK, BM
- 916 HOPE-SAM design and clinical management: BA, MB, PK, AJP, KN
- 917 Statistical review: MS, RN

Phiri et al, preprint

- 918 Study design: CDB
- 919 Statistical analysis: CDB
- 920 Drafted manuscript: CDB
- 921 Reviewed manuscript and approved submission: all co-authors

922

923 COMPETING INTERESTS

Authors declare that they have no competing interests.

925

926 DATA AND MATERIALS AVAILABILITY

- 927 Requests for further information, resources and reagents should be directed to the study
- 928 Principle Investigator, Claire D. Bourke (<u>c.bourke@qmul.ac.uk</u>). Participant samples were
- 929 collected in Zambia and Zimbabwe under local ethical approval and consenting procedures
- and are therefore restricted my Material Transfer Agreements.

Phiri et al, preprint



Figure 1. Circulating neutrophils and monocytes from children with SAM have 936 enhanced bacterial binding capacity compared to healthy controls. A) Representative 937 flow cytometry of bacterial binding by all single leukocytes from a healthy control (left) 938 relative to a SAM inpatient (right) with median and IQR for each group. B) tSNE plot of 500 939 E. coli+ single leukocytes per sample clustered by cell surface markers (Lin, CD66b, CD14, 940 CD16 and HLA-DR) colour-coded by healthy control (pink) and SAM (blue) group; plots 941 separated by group (right). C) Total single leukocyte count, D) total E. coli+ single leukocyte 942 count, E) total E. coli+ leukocytes as a percentage of all single leukocytes, and F) mean 943 944 AF488 FI of all single leukocytes from flow cytometry analysis of healthy controls (grey, n=81) versus SAM inpatients (red; n=137). G) Leukocyte sub-types as a percentage of total 945 E. coli+ leukocytes, and H) monocyte sub-sets as a percentage of total E. coli+ monocytes. I) 946

| 948 | E. coli+ cells as a percentage of all cells of that type, and J) E. coli+ monocyte sub-sets as a |
|-----|--|
| 949 | percentage of all cells of the sub-set. Mean AF488 FI of K) neutrophils, L) lymphocytes, M) |
| 950 | monocytes and N) monocyte sub-sets. Violin plots indicate median (dark line) and IQR |
| 951 | (dashed lines); coefficients (Coef.) and p-values are reported for unadjusted univariable |
| 952 | negative binomial regression of event counts (C, D), linear regression of mean AF488 FI (F, |
| 953 | K-N), and fractional regression of proportions (E, G-J) by SAM status. |

Phiri et al, preprint





Figure 2. SAM compromises monocyte maturation and pro-inflammatory mediator 956 secretion in response to bacterial PAMP. Whole blood samples from children with SAM 957 958 (red) and healthy controls (grey) were incubated for 24h in media alone, LPS or HKST; cultured cells were analysed by flow cytometry (A-D; Healthy controls, n=88; SAM, n=136) 959 and culture supernatants were analysed by ELISA (E-F; Healthy controls, n=91; SAM, 960 n=136). A) Flow cytometry gating of total monocytes after exclusion of cells expressing 961 markers of lymphocyte and granulocyte lineage; representative example. PAMP-induced 962 median FI of B) Δ HLA-DR-PECy7, C) Δ CD86-FITC, and D) Δ CD40-PerCP-Cy5.5 of total 963 monocytes after subtraction of median FI in unstimulated cultures. E) LPS-induced and F) 964 HKST-induced Δ IL-6, Δ IL-8, Δ TNF α and Δ MPO after subtraction of concentrations in 965 unstimulated cultures. Violin plots indicate median (dark line) and IOR (dashed lines); 966 coefficients (Coef.) and p-values are reported for unadjusted tobit regression by group. 967 968

Phiri et al, preprint





971 Figure 3. Monocytes and neutrophils of children with SAM prioritise bacterial

containment over systemic immune activation. A) Factor loadings for all anti-anti-bacterial 972 innate immune function variables included in a principal components analysis (126 children 973 with SAM and 73 healthy controls with full data). Table colour-coded by strength and 974 direction of association between the original variables and the resulting principal components 975 (PC) with red indicating positive (bold for coefficient ≥ 0.3) and blue negative (bold for 976 coefficient \leq -3) association. Percentages correspond to the amount of variance in the dataset 977 978 accounted for by each PC. Functional interpretation reflects the combination of the original variables captured by each PC. Scores for B) PC1, C) PC2, D) PC3, E) PC4 and F) PC5 for 979 each child in the SAM (red) and healthy control (grey) groups. Violin plots indicate median 980 (dark line) and IQR (dashed lines); coefficients (Coef.) and p-values are reported for 981 multivariable linear regression by SAM status, adjusting for sex, age group, HIV status, 982 hospital site and immunoassay on the day of discharge. 983

Phiri et al, preprint







Figure 4. SAM differentiates innate anti-bacterial immune cell function from healthy 987 controls among HIV-negative children and among children who had immune 988 assessment prior to the day of discharge. Scores for A) PC1, B) PC2, C) PC3, D) PC4 and 989 E) PC5 for HIV negative children in the healthy control (grey) and SAM (red) groups; 990 coefficients (Coef.) and p-values are reported for multivariable linear regression by SAM 991 status, adjusting for variation due to sex, age group, hospital site and immunoassay on the day 992 of discharge. Scores for F) PC1, G) PC2, H) PC3, I) PC4 and J) PC5 for HIV for healthy 993 994 controls (grey) and children in the SAM group for whom an immunoassay was conducted prior to the day of hospital discharge; coef. and p-values are reported for multivariable linear 995 regression by SAM status, adjusting for variation due to sex, age group, HIV status and 996 hospital site. 997

Phiri et al, preprint



999



Phiri et al, preprint



1012



Phiri et al, preprint

1024 TABLES

1025

Table 1. Summary of available data on baseline demographic and clinical

1027 characteristics of the SAM and Healthy control groups of the IMMUNO-SAM cohort

| 1028 | |
|------|--|
|------|--|

Healthy Controls SAM Inpatients N 92 141 92/174 (52.9%) 141/745 (18.9%) Of HOPE-SAM cohort, n/N (%) Of HOPE-SAM blood samples, n/N (%) 92/173 (53.2%) 141/630 (22.4%) Hospital site¹: - Harare Central Hospital, n/N (%) 54/141 (38.3%) 38/92 (41.3%) - Parirenyatwa Hospital, n/N (%) 40/92 (43.5%) 60/141 (42.6%) - University Teaching Hospital, n/N (%) 14/92 (15.2%) 27/141 (19.2%) Inpatient mortality², n/N 0/141 (0%) Time to discharge, days; median (IQR) [n] 11.0 (7, 16) [141] Participant withdrew, n/N 0/141(0%)Discharge against medical advice, n/N (%) 8/132 (6.1%) Participant characteristics (baseline): 19.3 (13, 22) [141] Age (mo), median (IQR) [n] 26.0 (18, 40) [92] 7/141 (5.0%) $- < 6 \text{ mo}^3$ 0/92 (0.0%) - 6-11 mo³ 12/92 (13.0%) 17/141 (12.1%) - 12-23 mo 30/92 (32.6%) 92/141 (65.3%) - 24-59 mo 50/92 (54.3%) 25/141 (17.73%) Male, n/N (%) 37/92 (40.2%) 71/141 (49.7%) Cerebral palsy, n/N (%) 0/92(0.0%)7/141 (5.0%) Birthweight (kg); mean (SD) [n] 3.0 (0.5) [86] 2.9 (0.6) [126] Cessation of breastfeeding <6 mo; n/N (%) 0/92 (0%) 10/141 (7.1%) **HIV status:** HIV positive, n/N (%) 32/92 (34.8%) 33/141 (23.4%) - On ART, n/N (%) 32/32 (100%) 14/33 (42.4%) - On CTX, n/N (%) 26/31 (83.9%) 19/28 (67.9%) HIV-exposed uninfected, n/N (%) 22/92 (23.9%) 19/141 (13.5%) HIV-unexposed uninfected, n/N (%) 34/92 (37.0%) 89/141 (63.1%) Nutritional status (baseline): Edematous SAM, n/N (%) 98/141 (69.5%) MUAC (mm), mean (SD) [n] 151.6 (12.2) [90] 119.7 (18.9) [141] WHZ score, mean (SD) [n] 0.4 (0.9) [91] -2.7 (1.5) [141] WAZ score, mean (SD) [N] -0.6 (1.1) [92] -3.6 (2.0) [141] HAZ score, mean (SD) [n] -1.6 (1.5) [92] -2.9 (1.5) [141] Stunting status (HAZ<-2), n/N (%) 35/92 (38.0%) 68/141 (48.2%) Systemic inflammatory mediators (baseline): Plasma CRP (mg/L); median (IQR) [n] 0.2 (0.0, 1.4) [92] 1.5 (0.2, 8.3) [119] Plasma sCD14 (µg/mL), median (IQR) [n] 1.5 (1.0, 2.0) [92] 1.8 (1.3, 2.2) [116] Plasma sCD163 (pg/mL); median (IQR) [n] 979 (700, 1289) [91] 1279 (823, 2129) [117] Plasma LBP (µg/mL); median (IQR) [n] 3.1 (2.0, 5.0) [91] 8.6 (4.9, 12.5) [116] Intestinal inflammatory mediators (baseline): Stool MPO (ng/mL); median (IQR) [n] 1657 (390, 3213) [76] 1462 (946, 4933) [47] Stool Neopterin (nmol/L); median (IQR) [n] 373 (148, 960) [79] 787 (442, 2057) [33] Clinical signs & symptoms (day of immunoassay): Time to first immunoassay, days; median (IQR) [n] 6.0 (4, 11) [137] Any symptom⁴, n/N (%) 105/130 (80.8%) Number of symptoms; median (IQR) [n] 2.0 (2, 4) [105] Any symptom associated with infection⁵; n/N (%) 78/130 (60.0%) Number of infectious symptoms, median (IQR) [n] 2.0 (1, 2) [78]

¹⁰²⁹ ¹Immune function assessments were undertaken in centralized laboratories in Zimbabwe for (Harare Central and Parirenyatwa) and Zambia (University Teaching Hospital).

¹⁰³¹ ²Comparison of the SAM group to the wider HOPE-SAM cohort Is provided in **Table S1**.

³Age groups according to grouping for stratification for HOPE-SAM recruitment and analysis

1033 of mortality outcomes (9, 36); the <6mo and 6-11 mo age groups were combined for analyses.

- ⁴Participants were classified as having 'any symptom' if the study clinician recorded 'Yes' to
 any of the standardized list of signs/symptoms on the daily inpatient review form the day of
- 1037 hospitalization corresponding to the day of blood sampling.
- ¹⁰³⁸ ⁵Clinician review recorded 'Yes' to any sign/symptom likely to be caused by infection (i.e.
- 1039 persistent diarrhea, acute diarrhea, cough, sepsis, meningitis, measles in the past 3 months,
- 1040 malaria, TB (including suspected), skin infection, oral thrush, ear discharge, cannula site
- 1041 infection, UTI & any infections in free text 'other'); HIV status and sequelae due to congenital
- 1042 infections were not included.

| | | PC1 ^{1, 2} | PC2 ^{1, 3} | PC3 ^{1, 4} | PC4 ^{1, 5} | PC5 ^{1, 6} |
|-------------------------------|------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Baseline age group: | | | | | | |
| - 0-11mo | | Reference | | | | |
| | Adj. Coef. | 0.02 | -0.73 | 0.49 | 0.39 | 0.12 |
| - 12-23mo | 95%CI | -1.19, 1.23 | -1.76, 0.29 | -0.39, 1.35 | -0.42, 1.20 | -0.50, 0.75 |
| | Р | 0.976 | 0.162 | 0.268 | 0.348 | 0.703 |
| | Adj. Coef | -0.10 | -0.89 | 0.56 | 1.16 | 0.12 |
| - 24-59mo | 95%CI | -1.49, 1.28 | -2.15, 0.37 | -0.43, 1.55 | 0.24, 2.08 | -0.64, 0.89 |
| | Р | 0.885 | 0.165 | 0.265 | 0.013 | 0.753 |
| HIV status: | | | | | | |
| - Negative | | Reference | | | | |
| | Adj. Coef. | -0.77 | 0.46 | -0.66 | -0.23 | 0.55 |
| - Positive | 95%CI | -1.80, 0.26 | -0.45, 1.37 | -1.28, -0.04 | -1.00, 0.55 | -0.11, 1.21 |
| | Р | 0.143 | 0.322 | 0.037 | 0.566 | 0.101 |
| Baseline edema status: | | | | | | |
| - Non-edematous | | Reference | | | | |
| | Adj. Coef. | 0.51 | 0.12 | 0.11 | 0.47 | -0.09 |
| - Edematous | 95%CI | -0.59, 1.61 | -0.87, 1.12 | -0.52, 0.75 | -0.17, 1.11 | -0.64, 0.45 |
| | Р | 0.363 | 0.809 | 0.723 | 0.152 | 0.741 |
| Symptom/s of infection | | | | | | |
| at time of immunoassay: | | | | | | |
| - None | | Reference | | | | |
| | Adj. Coef. | 0.28 | 0.33 | -0.10 | -0.07 | 0.10 |
| - ≥1 symptom | 95%CI | -0.62, 1.17 | -0.43, 1.09 | -0.63, 0.43 | -0.59, 0.46 | -0.36, 0.55 |
| | Р | 0.545 | 0.395 | 0.712 | 0.799 | 0.684 |
| | Adj. Coef. | -0.02 | 0.04 | 0.00 | 0.00 | 0.00 |
| Baseline MUAC (mm) | 95%CI | -0.06, 0.03 | 0.01, 0.07 | -0.02, 0.02 | -0.02, 0.02 | -0.03, 0.03 |
| | Р | 0.427 | 0.010 | 0.834 | 0.690 | 0.860 |

Table 2. Cross-fit partialling-out lasso regression of anti-bacterial innate immune function profiles (principal components) by demographic and clinical variables associated with inpatient and post-discharge mortality among children with SAM

n=109 children with SAM; fixed exposure variables selected based on HOPE-SAM mortality and morbidity outcomes(6, 9); controls offered to model: sex, hospital site, time to immunoassay, immune function assessment on the day of hospital discharge, baseline WHZ, baseline HAZ, birthweight & cerebral palsy status

²5 controls, Wald chi²: 3.20, p=0.783

³3 controls, Wald chi²: 9.45, p=0.150 ⁴3 controls, Wald chi²: 7.77, p=0.255

⁵3 controls, Wald chi²: 13.74, p=0.033 ⁶4 controls, Wald chi²: 3.33, p=0.760